ClinicalTrials.gg
TerminatedNCT04704050EDORAUpdated Oct 30, 2025Results posted

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

A Phase 4 interventional study of dronedarone 400 mg Oral Tablet and Placebo in Atrial Fibrillation and Atrial Fibrillation Recurrent, sponsored by Tulane University School of Medicine. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Tulane University School of Medicine · Phase 4, Interventional, and Prevention

How we know

Why this study was terminated
Sponsor withdrew funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
26th of 26
22 · median 164
Started
2021
with 1 other
Phase 4
11 of 26
2 open now
Registered
21st of 26
by date
Lead sponsor
1 of 26
Tulane University School of Medicine

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 26th largest by enrollment, is one of 2 that started in 2021, is one of 11 in phase 4, and was the 21st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

Patients who have undergone cardiac ablation will be randomized and blinded to one of two groups; one group will receive dronedarone while the other group will receive a placebo. The incidence of atrial fibrillation recurrence, as well as atrial fibrosis progression, will be analyzed between the two trial groups.

Read the detailed description

The purpose of this trial is to determine whether dronedarone is effective in slowing the progression of fibrosis and decreasing atrial fibrillation recurrence in patients who have undergone ablation therapy.

Patients with atrial fibrillation (AF) undergoing ablation will be stratified by age and gender (>65 years and \<65 years, male and female) as well as by type of atrial fibrillation (paroxysmal, persistent, etc.) and then randomized to one of two trial groups. They will either receive dronedarone 400 mg BID (twice daily) (treatment group) or placebo (control group). The control group will be started on placebo, and treating physicians will be advised to limit the initiation of anti-arrhythmic drugs (standard of care, SOC) to necessary cases only, avoiding amiodarone and dronedarone.

Each patient will receive a pre-ablation Cardiac Magnetic Resonance imaging (CMR) (SOC) scan, followed by scans at 3 and 12-month post-ablation. Quality of Life (QoL) changes will be evaluated from baseline and at 3 months and 12-months via the Atrial Fibrillation Effect on Quality-Of-Life (AFEQT) online questionnaire form. AF burden (frequency, duration and severity of an AF episode) if present, will be evaluated from baseline and at 3 months and 12-months via the Atrial Fibrillation Severity Scale (AFSS) online questionnaire form.

Patients will be followed post-ablation for AF recurrence and burden assessment with a continuous 30-day ECG wearable patch starting at discharge (SOC), then at 3,6,9 and 12 months post-ablation

Phone call visits will occur at 6 and 9 months to monitor for medication compliance as well as to assess that devices are working accordingly. Evaluation of adverse events (AE's) as well as whether a patient has reached any trial endpoints will be analyzed at this time.

Physicians will be advised to avoid adjustments in drug therapy unless necessary (severely symptomatic patients, patients with heart failure). Severely symptomatic patients will be defined as, patients with non-tolerated palpitations or chest pain, dizziness, syncope, dyspnea, or suddenly reduced ability to exercise.

Any initiation or change of an anti-arrhythmic treatment in the treatment or control group will be considered as a secondary endpoint. Patients will continue to be monitored for fibrosis progression and AF burden via CMR scans and ECG wearable devices until the end of the follow-up period. In the case of AF recurrence after ablation, anti-arrhythmic drugs (AAD) initiation or change will be left to the discretion of the treating physician.

03

Conditions studied

  • Atrial Fibrillation
  • Atrial Fibrillation Recurrent

Keywords

  • Atrial Fibrillation
  • Atrial Fibrillation Recurrent
  • Heart Murmur
  • Dronedarone
  • Atrial Fibrosis
  • Atrial Fibrosis Progression
  • Atrial Fibrosis Regression
  • Atrial Arrhythmia
  • Cardiac Arrhythmia
  • Cardiovascular Events
  • Multaq
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients must meet the following criteria to be enrolled in the trial.

  • Male or female patients aged over 18 years of age.
  • Patients with paroxysmal or persistent atrial fibrillation who are undergoing ablation of atrial fibrillation, regardless of whether they were receiving an anti-arrhythmic drug (AADs) before enrollment or not.

Exclusion Criteria: Patients will be excluded from enrollment if any of the following criteria are present.

  • Any health-related gadolinium/MRI (e.g. allergy to gadolinium, pacemakers, Implantable Cardioverter Defibrillators [ICD's], other devices/implants contraindicated for use of MRI, etc.).
  • Patients weighing >300 Ibs. (MRI quality decreases as increases).
  • Patients with contraindications to dronedarone. (Including patients with decompensated heart failure or class IV (New York Heart Association Class IV), second or third-degree atrioventricular (AV) block or sick-sinus syndrome [except when used in conjunction with a functioning pacemaker]), concomitant use of strong cytochrome P450, family 3, subfamily A (CYP-3A) inhibitors or other Class I or III AADs, drug or herbal products that prolongs the and may induce Torsades de Pointes.
  • Liver or lung toxicity related to the previous use of amiodarone, severe hepatic impairment including any stage of cirrhosis and acute liver failure, bradycardia \<50bpm, QTc Bazett interval >500ms or PR interval >280ms, or to the active substance or to any of its .
  • Acute or chronic severe renal disease with a low (GFR), \<30 mL per minute per 1.73m2 will be excluded from the trial.
  • Patients with a history of prior left atrial ablation or valvular cardiac surgery (myocardial scarring/fibrosis from prior surgeries may confound data).
  • Pre-menopausal (last menstruation \<1 year prior to screening) who:

    1. are pregnant or breast-feeding or plan to become pregnant during the study period or,
    2. are not surgically sterile or,
    3. are of and not practising two acceptable methods of or,
    4. do not plan to continue practising two acceptable methods of birth control throughout the trial (highly effective methods of birth control are defined as those, used alone, or in combination, that result in a low failure rate i.e. less than 1% per year when used consistently and correctly).
  • Patients who do not have access to the Internet/e-mail.
  • Patients without daily access to a smart phone-compatible with Check device application and ability to upload ECG tracings for the entire follow-up period.
  • Patients unable or unwilling to return to the clinic for follow up CMR scans.
  • Patients with cognitive impairments who are unable to give .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    Treatment Group

    Dronedarone 400 mg orally, twice per day (BID)

    Drug: dronedarone 400 mg Oral Tablet

  • Placebo comparator
    Control Group

    Placebo tablet orally, twice per day (BID)

    Drug: Placebo

Interventions

  • DrugDronedaroneStudies of DronedaroneDronedarone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV. Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks.

    Also known as: Multaq®

  • DrugPlacebo

    Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Post-ablation Atrial Fibrillation Recurrence

    Investigators monitored subjects upon discharge, 24-48 hours after AF ablation. This was recorded by either the occurrence of a single positive atrial arrhythmias (AA) ECG reading on a 12-lead ECG, Holter monitor, obtained on the daily event strips from the Preventice monitoring device, or 30-day monitoring patch.

    Time frame: Up to 56 weeks. From date of ablation until the date of first documented Atrial Fibrillation recurrence, whichever came first, assessed up to 56 weeks.

  2. Post-ablation Atrial Fibrillation Recurrence Documented by an AAD Initiation

    New anti-arrhythmic drug (AAD) initiation for AF recurrence after AF ablation, including initiation of the treatment during the blanking period, or with no available positive ECG reading.

    Time frame: Up to 56 weeks. From date of ablation until the date of first documented Atrial Fibrillation recurrence, whichever came first, assessed up to 56 weeks.

Secondary outcomes

  1. Atrial Fibrillation Episodes

    Atrial arrhythmia (AA) episodes associated with palpitations, chest pain, dyspnea, dizziness, syncope, or unusual fatigue and weakness were assessed using the Atrial Fibrillation Severity Scale (AFSS) questionnaire. The AFSS is a validated questionnaire designed to measure the burden of atrial arrhythmias, including atrial fibrillation and other irregular heart rhythms. The AA symptom burden score is derived from the AFSS summary score, which averages the frequency, duration, and patient-perceived severity of AA episodes. The AFSS symptom burden score ranges from 3 to 30, with higher scores indicating greater AA burden. Subscale scores (frequency, duration, and severity) are each rated on a scale of 1 to 10 and are averaged to calculate the total burden score. Patients completed the AFSS at baseline, 3 months, and 12 months. Reported data in the results table reflect the mean score at the 12-month time point.

    Time frame: At baseline, at month 3, at month 12

  2. Repeat Cardiac Ablation

    Whether patients in either treatment arm require a repeat cardiac ablation.

    Time frame: 1 year

  3. Cardioversion

    Whether patients in either treatment arm require cardioversion.

    Time frame: 1 year

  4. Atrial Fibrillation Burden

    The percentage of time a patient is in atrial fibrillation during the monitoring period, 24-48 hours and, at 3 months and 12 months post-ablation. Burden will be recorded as a time-weighted average (%) based on data from wearable devices.

    Time frame: 1 year

  5. Quality of Life (Online Questionnaire Form)

    Quality of life (QoL) was assessed through the Atrial Fibrillation Severity Scale (AFSS), a validated instrument that evaluates the impact of AF across multiple domains, including symptom burden, health care utilization, and overall well-being. The Global Well-being domain of the AFSS is assessed using a single-item question (A4), which measures overall quality of life on a scale from 1 to 10, where higher scores indicate better quality of life. Patients completed the questionnaire at baseline, 3 months, and 12 months. The reported data in the results table reflect the mean score at the 12-month time point.

    Time frame: At baseline, at month 3, at month 12

  6. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Assessment of adverse events related to treatment given. Evaluated at 3, 12 months visits and during 6 \& 9 month phone call visits.

    Time frame: Through trial completion, up to 56 weeks.

Other outcomes

  1. Hospitalization

    Records of any cardiac events requiring hospitalization.

    Time frame: 1 year

  2. Mortality

    Records of mortality associated with cardiovascular events.

    Time frame: 1 year

  3. Stroke/ Transient Ischemic Attacks (TIA)

    Records of stroke or TIA based on cardiac emboli.

    Time frame: 1 year

07

Results

Posted Oct 16, 2025
Limitations and caveats
Early termination and incomplete data collections for several outcome measures. All data that was collected was added to the results section for this study.

Participant flow

Participant flow — Overall Study
MilestoneTreatment GroupControl Group
Started1210
Completed67
Not completed63

Outcome measures

PrimaryPost-ablation Atrial Fibrillation Recurrence

Investigators monitored subjects upon discharge, 24-48 hours after AF ablation. This was recorded by either the occurrence of a single positive atrial arrhythmias (AA) ECG reading on a 12-lead ECG, Holter monitor, obtained on the daily event strips from the Preventice monitoring device, or 30-day monitoring patch.

Time frame:
Up to 56 weeks. From date of ablation until the date of first documented Atrial Fibrillation recurrence, whichever came first, assessed up to 56 weeks.
Reported as:
Count of participants · Participants
Post-ablation Atrial Fibrillation Recurrence
ParticipantsTreatment GroupControl Group
Post-ablation Atrial Fibrillation Recurrence21
PrimaryPost-ablation Atrial Fibrillation Recurrence Documented by an AAD Initiation

New anti-arrhythmic drug (AAD) initiation for AF recurrence after AF ablation, including initiation of the treatment during the blanking period, or with no available positive ECG reading.

Time frame:
Up to 56 weeks. From date of ablation until the date of first documented Atrial Fibrillation recurrence, whichever came first, assessed up to 56 weeks.
Reported as:
Count of participants · Participants
Post-ablation Atrial Fibrillation Recurrence Documented by an AAD Initiation
ParticipantsTreatment GroupControl Group
Post-ablation Atrial Fibrillation Recurrence Documented by an AAD Initiation12
SecondaryAtrial Fibrillation Episodes

Atrial arrhythmia (AA) episodes associated with palpitations, chest pain, dyspnea, dizziness, syncope, or unusual fatigue and weakness were assessed using the Atrial Fibrillation Severity Scale (AFSS) questionnaire. The AFSS is a validated questionnaire designed to measure the burden of atrial arrhythmias, including atrial fibrillation and other irregular heart rhythms. The AA symptom burden score is derived from the AFSS summary score, which averages the frequency, duration, and patient-perceived severity of AA episodes. The AFSS symptom burden score ranges from 3 to 30, with higher scores indicating greater AA burden. Subscale scores (frequency, duration, and severity) are each rated on a scale of 1 to 10 and are averaged to calculate the total burden score. Patients completed the AFSS at baseline, 3 months, and 12 months. Reported data in the results table reflect the mean score at the 12-month time point.

Time frame:
At baseline, at month 3, at month 12
Reported as:
Mean · Scores on a scale
Atrial Fibrillation Episodes
Scores on a scaleTreatment GroupControl Group
Atrial Fibrillation Episodes7.5 ± 1.737.8 ± 2.17
SecondaryRepeat Cardiac Ablation

Whether patients in either treatment arm require a repeat cardiac ablation.

Time frame:
1 year
Reported as:
Count of participants · Participants
Repeat Cardiac Ablation
ParticipantsTreatment GroupControl Group
Repeat Cardiac Ablation10
SecondaryCardioversion

Whether patients in either treatment arm require cardioversion.

Time frame:
1 year
Reported as:
Count of participants · Participants
Cardioversion
ParticipantsTreatment GroupControl Group
Cardioversion21
SecondaryAtrial Fibrillation Burden

The percentage of time a patient is in atrial fibrillation during the monitoring period, 24-48 hours and, at 3 months and 12 months post-ablation. Burden will be recorded as a time-weighted average (%) based on data from wearable devices.

Time frame:
1 year
Reported as:
Mean · Percentage of time
Atrial Fibrillation Burden
Percentage of timeTreatment GroupControl Group
Atrial Fibrillation Burden9 ± 4.554.5 ± 5.8
SecondaryQuality of Life (Online Questionnaire Form)

Quality of life (QoL) was assessed through the Atrial Fibrillation Severity Scale (AFSS), a validated instrument that evaluates the impact of AF across multiple domains, including symptom burden, health care utilization, and overall well-being. The Global Well-being domain of the AFSS is assessed using a single-item question (A4), which measures overall quality of life on a scale from 1 to 10, where higher scores indicate better quality of life. Patients completed the questionnaire at baseline, 3 months, and 12 months. The reported data in the results table reflect the mean score at the 12-month time point.

Time frame:
At baseline, at month 3, at month 12
Reported as:
Mean · Scores on a scale
Quality of Life (Online Questionnaire Form)
Scores on a scaleTreatment GroupControl Group
Quality of Life (Online Questionnaire Form)8.8 ± 1.3010 ± 0
SecondaryIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Assessment of adverse events related to treatment given. Evaluated at 3, 12 months visits and during 6 \& 9 month phone call visits.

Time frame:
Through trial completion, up to 56 weeks.
Reported as:
Number · Events
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
EventsTreatment GroupControl Group
Anemia10
Fatigue10
Hypoxemia10
Elevated creatinine10
Thrombocytopenia10
Dyspnea10
Dyspnea on effort10
Increased Troponin10
Intermittent Nausea10
Intermittent Headache10
Upset Stomach10
Right shoulder pain10
Right rotator cuff tear10
Elevated uric acid levels01
Excessive flatulence01
Hemorrhoids10
Prostate hyperplasia10
Hypertension01
Worsening of Hyperlipidemia01
Right lung mass01
Increased shoulder pain01
Leukocytosis01
Nausea10
Diarrhea10
Rash on Chest10
Spinal Stenosis10
Urinary incontinence10
Erectile dysfunction10
Other pre-specifiedHospitalization

Records of any cardiac events requiring hospitalization.

Time frame:
1 year
Reported as:
Number · Events
Hospitalization
EventsTreatment GroupControl Group
Anemia10
Chest Pain01
Dizziness01
Dyspnea01
Hematuria01
GERD01
Peripheral neuropathy10
Increased Troponin10
Right lower extremity swelling01
Left lower extremity swelling01
Left upper extremity swelling01
Acute gout flare-up01
Cellulitis01
Fluid Overload01
Acute Kidney Injury01
Acute Tubular Necrosis01
Hyperkalemia01
Hypotension01
Other pre-specifiedMortality

Records of mortality associated with cardiovascular events.

Time frame:
1 year
Reported as:
Count of participants · Participants
Mortality
ParticipantsTreatment GroupControl Group
Mortality00
Other pre-specifiedStroke/ Transient Ischemic Attacks (TIA)

Records of stroke or TIA based on cardiac emboli.

Time frame:
1 year
Reported as:
Count of participants · Participants
Stroke/ Transient Ischemic Attacks (TIA)
ParticipantsTreatment GroupControl Group
Stroke/ Transient Ischemic Attacks (TIA)00

Adverse events

Collected over 13 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Group0/12 (0%)2/12 (16.7%)2/12 (16.7%)
Control Group0/10 (0%)3/10 (30%)3/10 (30%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventTreatment GroupControl Group
HospitalizationCardiac disorders2/123/10
DizzinessEar and labyrinth disorders0/121/10
DyspneaCardiac disorders0/121/10
HematuriaRenal and urinary disorders0/121/10
GERDGastrointestinal disorders0/121/10
Chest PainCardiac disorders0/121/10
Right lower extremity swellingVascular disorders0/121/10
Left lower extremity swellingVascular disorders0/121/10
Left upper extremity swellingVascular disorders0/121/10
Acute gout flare-upMusculoskeletal and connective tissue disorders0/121/10
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTreatment GroupControl Group
HypertensionCardiac disorders0/121/10
Worsening of HyperlipidemiaCardiac disorders0/121/10
LeukocytosisBlood and lymphatic system disorders0/121/10
Right lung massRespiratory, thoracic and mediastinal disorders0/121/10
Excessive flatulenceGastrointestinal disorders0/121/10
Increased shoulder painMusculoskeletal and connective tissue disorders0/121/10
Elevated uric acid levelsMusculoskeletal and connective tissue disorders0/121/10
DyspneaCardiac disorders1/120/10
Dyspnea on effortCardiac disorders1/120/10
ThrombocytopeniaBlood and lymphatic system disorders1/120/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment GroupControl GroupTotal
Median66 (55.25 to 78.25)64.50 (52.50 to 69.75)66 (53.75 to 72.50)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment GroupControl GroupTotal
Female6511
Male6511
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment GroupControl GroupTotal
Hispanic or Latino011
Not Hispanic or Latino10919
Unknown or Not Reported202
Region of Enrollment
Region of Enrollment(participants)Treatment GroupControl GroupTotal
United States121022
08

Study locations

4 sites
  • University of Colorado Health Memorial
    Colorado Springs, Colorado 80909, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Tulane University School of Medicine
    New Orleans, Louisiana 70112, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, Kingma JH, Crijns HJ, Van Gelder IC; RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004 Jan 21;43(2):241-7. doi: 10.1016/j.jacc.2003.08.037. PubMed 14736444 ↗
  • Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L, Kenneback G, Rubulis A, Malmborg H, Raatikainen P, Lonnerholm S, Hoglund N, Mortsell D. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial. JAMA. 2019 Mar 19;321(11):1059-1068. doi: 10.1001/jama.2019.0335. PubMed 30874754 ↗
  • Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bansch D; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018 Feb 1;378(5):417-427. doi: 10.1056/NEJMoa1707855. PubMed 29385358 ↗
  • Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693. PubMed 30874766 ↗
  • Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P, Brachmann J. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014 Feb 5;311(5):498-506. doi: 10.1001/jama.2014.3. PubMed 24496537 ↗
  • Kheirkhahan M, Baher A, Goldooz M, Kholmovski EG, Morris AK, Csecs I, Chelu MG, Wilson BD, Marrouche NF. Left atrial fibrosis progression detected by LGE-MRI after ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2020 Apr;43(4):402-411. doi: 10.1111/pace.13866. PubMed 31867751 ↗
  • Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78. doi: 10.1056/NEJMoa0803778. PubMed 19213680 ↗
  • Akoum N, Fernandez G, Wilson B, Mcgann C, Kholmovski E, Marrouche N. Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2013 Oct;24(10):1104-9. doi: 10.1111/jce.12199. Epub 2013 Jul 11. PubMed 23844972 ↗
  • Marrouche NF, Dagher L, Wazni O, Akoum N, Mansour M, El Hajjar AH, Bhatnagar A, Hua H; EDORA Investigators. Effect of DrOnedarone on atrial fibrosis progression and atrial fibrillation recurrence postablation: Design of the EDORA randomized clinical trial. J Cardiovasc Electrophysiol. 2021 Dec;32(12):3203-3210. doi: 10.1111/jce.15274. Epub 2021 Nov 2. PubMed 34664772 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Dec 2022, 19 months.

Results were first posted in Oct 2025, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2021
First posted
Jan 11, 2021
StartActual
May 15, 2021
Primary completionActual
Dec 20, 2022
CompletionActual
Dec 20, 2022
Results first posted
Oct 16, 2025
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04704050
Lead sponsor
Tulane University School of Medicine
Collaborators
University of Washington, Marrek, INC, Sanofi, Preventice, Mckesson
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
May 15, 2021
Primary completion
Dec 20, 2022
Completion
Dec 20, 2022
Results posted
Oct 16, 2025
Last update
Oct 30, 2025

Study contacts

Nassir F Marrouche, MD
principal investigator · Tulane University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion